Cyanotech (CYAN)
OTHER OTC:CYAN
Want to see CYAN full AI Analyst Report?
CYAN Stock Chart & Stats
$0.35
$0.00(0.00%)
At close: 4:00 PM EST
$0.35
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.21 - $0.57
Previous CloseN/A
VolumeN/A
Average Volume (3M)6.46K
Market Cap
$2.77M
Enterprise Value$14.21M
Total Cash (Recent Filing)$649.00K
Total Debt (Recent Filing)$15.07M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Jun 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding7,392,243
10 Day Avg. Volume1,585
30 Day Avg. Volume6,463
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.28
Price to Sales (P/S)0.10
P/FCF Ratio-1.72
Enterprise Value/Market Cap5.13
Enterprise Value/Revenue0.56
Enterprise Value/Gross Profit1.76
Enterprise Value/Ebitda15.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue StreamsCyanotech's dual model—branded finished goods plus bulk ingredient sales—creates durable revenue diversification. Over 2-6 months this reduces reliance on a single channel, lets the company capture higher value from branded sales while preserving volume-driven bulk contracts tied to cultivation output and yield.
Moderate Product-level Gross MarginA near-30% gross margin indicates underlying unit economics for spirulina and astaxanthin are viable. This product-level profitability gives room to absorb SG&A and improve operating margins via mix shifts toward branded items or yield improvements, offering a path to sustainable profitability if variable costs and yields stabilize.
Substantial Asset Base Supports ScaleOwning cultivation and processing assets is a durable competitive advantage in microalgae production; it enables volume scaling without immediate large incremental capex and protects proprietary cultivation know-how. Over several months, existing capacity can support higher volumes when demand or yields improve.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow and a material decline in free cash flow signal cash-generation problems. This constrains the company's ability to fund working capital, maintenance capex, or marketing for branded growth, increasing reliance on external financing and creating liquidity pressure over the medium term.
High LeverageA debt-to-equity ratio near 1.5 materially raises interest and refinancing risk, limiting strategic flexibility. With negative margins and weak cash flows, high leverage increases the probability that debt servicing will crowd out reinvestment or force dilution, a structural constraint over multiple quarters.
Negative Net And Operating MarginsLoss-making net and operating margins show the company fails to convert gross profits into positive operating returns. Structural cost inefficiencies, pricing pressures, or low yields must be addressed; otherwise, continued losses will erode equity and make funding operations and growth unsustainable over the medium term.
Cyanotech News
CYAN FAQ
What was Cyanotech’s price range in the past 12 months?
Cyanotech lowest stock price was $0.21 and its highest was $0.57 in the past 12 months.
What is Cyanotech’s market cap?
Cyanotech’s market cap is $2.77M.
When is Cyanotech’s upcoming earnings report date?
Cyanotech’s upcoming earnings report date is Jun 30, 2026 which is in 55 days.
How were Cyanotech’s earnings last quarter?
Currently, no data Available
Is Cyanotech overvalued?
According to Wall Street analysts Cyanotech’s price is currently Overvalued.
Does Cyanotech pay dividends?
Cyanotech does not currently pay dividends.
What is Cyanotech’s EPS estimate?
Cyanotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyanotech have?
Cyanotech has 7,392,243 shares outstanding.
What happened to Cyanotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cyanotech?
Currently, no hedge funds are holding shares in CYAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cyanotech
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae worldwide. The company's products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant to enhance skin, and to support eye, joint and immune health, as well as used as a human dietary supplement and dietary ingredient; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, which is used for extra energy, strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. It also provides contract extraction services. The company sells its products through distributors, retailers, and online channels; direct to consumers; and in bulk form to manufacturers, formulators, and distributors in the health foods, nutraceuticals, and dietary supplement markets. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
Technical Analysis
Nature's Sunshine Products
―
Seneca Foods
―
Hain Celestial
―
USANA Health
―
Laird Superfood
―
Ownership Overview
Options Prices
Currently, No data available
---